RGMP
Regnum Corp. [RGMP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RGMP Stock Summary
In the News
RGMP Financial details
Company Rating
Sell
Market Cap
135.41K
Income
-338.35K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-0.26
Forward P/E
-
PEG
-0.09
P/S
-
P/B
-0.1
P/C
-
P/FCF
-0.17
Quick Ratio
0.25
Current Ratio
0.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
193.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-105%
ROE
44%
ROC
0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0059-0.8
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
4.5K
Volume
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.788
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0059
Change
0%
RGMP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | -0.01 | -0.03 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | -0.03 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | -0.03 | |
| Cash per share | 0 | 0 | 0 | 0.06 | 0.03 | |
| Book value per share | 0 | 0 | 0 | -0.02 | -0.05 | |
| Tangible book value per share | 0 | 0 | 0 | -0.02 | -0.05 | |
| Share holders equity per share | 0 | 0 | 0 | -0.02 | -0.05 | |
| Interest debt per share | 0 | 0 | 0 | 0.07 | 0.07 | |
| Market cap | 3.44M | 1.95M | 5.93M | 3.51M | 3.1M | |
| Enterprise value | 3.4M | 1.94M | 5.93M | 3.53M | 3.87M | |
| P/E ratio | 1.72K | -53.62 | -50.38 | -13 | -3.97 | |
| Price to sales ratio | 160.86 | 309.64 | 658.73 | 0 | 0 | |
| POCF ratio | 851.05 | -50.21 | -1.61K | -302.85 | -4.39 | |
| PFCF ratio | 1.06K | -48.95 | -612.96 | -302.85 | -4.39 | |
| P/B Ratio | 78.13 | 254 | -117.65 | -9.23 | -2.67 | |
| PTB ratio | 78.13 | 254 | -117.65 | -9.23 | -2.67 | |
| EV to sales | 158.65 | 308.46 | 658.73 | 0 | 0 | |
| Enterprise value over EBITDA | 839.36 | -55.18 | -52.53 | -9.58 | -5.26 | |
| EV to operating cash flow | 839.36 | -50.02 | -1.61K | -304.76 | -5.49 | |
| EV to free cash flow | 1.05K | -48.76 | -612.96 | -304.76 | -5.49 | |
| Earnings yield | 0 | -0.02 | -0.02 | -0.08 | -0.25 | |
| Free cash flow yield | 0 | -0.02 | 0 | 0 | -0.23 | |
| Debt to equity | 0 | 0 | 0 | -3.98 | -1.34 | |
| Debt to assets | 0 | 0 | 0 | 1.01 | 1.8 | |
| Net debt to EBITDA | -11.69 | 0.21 | 0 | -0.06 | -1.05 | |
| Current ratio | 13.01 | 9.31 | 0.08 | 0.8 | 0.43 | |
| Interest coverage | 0 | 0 | 0 | 0 | -16.35 | |
| Income quality | 2.02 | 1.07 | 0.03 | 0.04 | 0.9 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.81 | 6.59 | 13.29 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.12 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.2 | 0.03 | 1.63 | 0 | 0 | |
| Capex to revenue | -0.04 | -0.16 | -0.67 | 0 | 0 | |
| Capex to depreciation | -1.33 | -2.75 | -1.25 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
| Graham number | 0 | 0 | 0.02 | 0.07 | 0.2 | |
| ROIC | 0.05 | -4.74 | 2.34 | -0.33 | -1.86 | |
| Return on tangible assets | 0.04 | -4.89 | -26.15 | -0.18 | -0.9 | |
| Graham Net | 0 | 0 | 0 | -0.02 | -0.05 | |
| Working capital | 43.66K | 6.64K | -50.39K | -379.82K | -1.16M | |
| Tangible asset value | 43.66K | 6.64K | -50.39K | -379.82K | -1.16M | |
| Net current asset value | 43.66K | 6.64K | -50.39K | -379.82K | -1.16M | |
| Invested capital | 0 | 0 | 0 | -3.98 | -1.34 | |
| Average receivables | 0 | 0 | 2.25K | 2.25K | 0 | |
| Average payables | 1.33K | 662.5 | 27.05K | 197.64K | 319.03K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 182.5 | 0 | 0 | |
| Days payables outstanding | 806.04 | 0 | 8.86K | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 2 | 0 | 0 | |
| Payables turnover | 0.45 | 0 | 0.04 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.05 | -4.74 | 2.34 | 0.71 | 0.67 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
| Operating cash flow per share | -0.02 | -0.01 | -0.01 | 0 | 0 | |
| Free cash flow per share | -0.02 | -0.01 | -0.01 | 0 | 0 | |
| Cash per share | 0.04 | 0.03 | 0.02 | 0 | 0 | |
| Book value per share | -0.04 | -0.05 | -0.06 | 0 | 0 | |
| Tangible book value per share | -0.04 | -0.05 | -0.06 | 0 | 0 | |
| Share holders equity per share | -0.04 | -0.05 | -0.06 | 0 | 0 | |
| Interest debt per share | 0.07 | 0.07 | 0.07 | 0 | 0 | |
| Market cap | 3.44M | 3.1M | 3.48M | 0 | 0 | |
| Enterprise value | 4.07M | 3.87M | 4.58M | 0 | 0 | |
| P/E ratio | -4.69 | -5.66 | -4.31 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -9.82 | -23.85 | -10.85 | 0 | 0 | |
| PFCF ratio | -9.82 | -23.85 | -10.85 | 0 | 0 | |
| P/B Ratio | -3.36 | -2.67 | -2.57 | 0 | 0 | |
| PTB ratio | -3.36 | -2.67 | -2.57 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -25.32 | -30.86 | -25.55 | 0 | 0 | |
| EV to operating cash flow | -11.63 | -29.8 | -14.29 | 0 | 0 | |
| EV to free cash flow | -11.63 | -29.8 | -14.29 | 0 | 0 | |
| Earnings yield | -0.05 | -0.04 | -0.06 | 0 | 0 | |
| Free cash flow yield | -0.1 | -0.04 | -0.09 | 0 | 0 | |
| Debt to equity | -1.51 | -1.34 | -1.16 | 0 | 0 | |
| Debt to assets | 1.48 | 1.8 | 3.16 | 0 | 0 | |
| Net debt to EBITDA | -3.92 | -6.16 | -6.16 | 0 | 0 | |
| Current ratio | 0.5 | 0.43 | 0.27 | 0 | 0 | |
| Interest coverage | -14.19 | -11.06 | -16.16 | 0 | 0 | |
| Income quality | 2.03 | 0.95 | 1.68 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.09 | 0.08 | 0.11 | 0 | 0 | |
| ROIC | -0.33 | -0.32 | -0.88 | 0 | 0 | |
| Return on tangible assets | -0.18 | -0.16 | -0.41 | 0 | 0 | |
| Graham Net | -0.05 | -0.05 | -0.06 | 0 | 0 | |
| Working capital | -1.02M | -1.16M | -1.35M | 0 | 0 | |
| Tangible asset value | -1.02M | -1.16M | -1.35M | 0 | 0 | |
| Net current asset value | -1.02M | -1.16M | -1.35M | 0 | 0 | |
| Invested capital | -1.51 | -1.34 | -1.16 | 0 | 0 | |
| Average receivables | 47.09K | 0 | 0 | 0 | 0 | |
| Average payables | 488.83K | 348.52K | 257.1K | 108.65K | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.18 | 0.12 | 0.15 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
RGMP Frequently Asked Questions
What is Regnum Corp. stock symbol ?
Regnum Corp. is a US stock , located in New york of Ny and trading under the symbol RGMP
What is Regnum Corp. stock quote today ?
Regnum Corp. stock price is $0.0059 today.
Is Regnum Corp. stock public?
Yes, Regnum Corp. is a publicly traded company.
Company Profile
- Volume Average 4.5K
- Market Capitalization 135.41K
- Employee 1
- CEO Mr. Robert J. Stubblefield CPA
- Headquarters New York,NY,US
- IPO Date 2019-05-29
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
